Rugvedapatel

1
Alzheimers Therapeutics Market to Reach USD
12.43 Billion By 2026
www.reportsanddata.com
2
Market Summary
Rising incidence of investment in biomarkers for
drug development is the major factor influencing
market growth. Market Size USD 6.8 billion in
2018, Market Growth - CAGR of 9.23, Market
Trends Rise in advanced diagnostics for early
detection, along with more specific drug
development, and emerging innovative diagnostics
technologies. The Alzheimers Therapeutics
Market is expected to reach USD 12.43 Billion by
2026, according to a new report by Reports and
Data. This can be mainly associated with the
growing pipeline drug development, investment in
biomarkers for drug development which are
expected to further accelerate the market growth
globally. Based on statistics, increase in
advanced diagnostics for early detection, along
with more specific drug development, and emerging
innovative diagnostics technologies are also some
of the factors that are also helping to grow the
size of the global market.
www.reportsanddata.com
3
Market Summary

• Alzheimer's disease (AD) is the most usual cause
  of dementia worldwide. The study of this disease
  is multifactorial, and pathophysiology is also
  complicated. According to several types of
  research, an exponential rise in the number of
  cases of AD, highlighting the need for developing
  an effective treatment. AD also imposes a
  tremendous emotional and financial trouble to the
  patient's family and society. The disease has
  been studied for more than a century, but
  memantine and acetylcholinesterase inhibitors are
  the only drugs currently recommended for its
  management. These drugs provide significant
  improvement alone but do less to change the
  disease process. The significant penetration into
  the molecular and cellular pathomechanism in AD
  over the previous few decades has given us
  considerable progress in the understanding of the
  disease. Several novel strategies that seek to
  revise the disease process have been developed.
  The notable developments in this direction are
  the tau-based and amyloid therapeutics, which
  could hold the key to treatment of AD shortly.
• Further key findings from the report suggest-
• Cholinesterase inhibitors therapeutics accounts
  for the largest share of 38.85 in 2018. It can
  also improve neuropsychiatric symptoms, such as
  depression or agitation.
• Generally prescribed cholinesterase inhibitors
  are galantamine (Razadyne), donepezil (Aricept),
  and rivastigmine (Exelon).
• Avail the inside scoop of the Sample report _at_
  https//www.reportsanddata.com/sample-enquiry-form
  /1364

www.reportsanddata.com
4
Market Summary

• Companies considered and profiled in this market
  study
• Eli Lilly and Company, Daiichi Sankyo Hoffmann-La
  Roche Ltd, Pfizer, Inc., Eisai Co., Ltd.,
  Novartis AG, H. Lundbeck A/S, TauRx Therapeutics
  Ltd, Forest Laboratories, Inc., AC Immun, Johnson
  Johnson, TauRx Pharmaceuticals Ltd, VTV
  Therapeutics
• For the purpose of this study, Reports and Data
  have segmented the global Alzheimers
  Therapeutics Market on the basis of Therapeutics,
  End-User, Diagnostics Type and Region
• Therapeutics  Outlook (Revenue, USD Million
  2016-2026)
• Cholinesterase inhibitors
• Pipeline Drugs
• NMDA receptor antagonist
• End User Outlook (Revenue, USD Million
  2016-2026)
• Hospital Pharmacies
• Retail Pharmacies
• e-Commerce

www.reportsanddata.com
5
Market Summary

• Diagnostics Type  Outlook (Revenue, USD Million
  2016-2026)
• Computed tomography (CT) scan
• Magnetic resonance imaging (MRI)
• Lumbar puncture test
• Electroencephalography (EEG)
• Others
• Regional Outlook (Revenue in USD Million
  20162026)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa (MEA)
• Download Summary https//www.reportsanddata.com/d
  ownload-summary-form/1364

www.reportsanddata.com
6
About Us
Reports and Data is a market research and
consulting company that provides syndicated
research reports, customized research reports,
and consulting services. Our solutions purely
focus on your purpose to locate, target and
analyze consumer behavior shifts across
demographics, across industries and help clients
make a smarter business decision. We offer
market intelligence studies ensuring relevant and
fact-based research across a multiple industries
including Healthcare, Technology, Chemicals,
Power, and Energy. We consistently update our
research offerings to ensure our clients are
aware about the latest trends existent in the
market. Reports and Data has a strong base of
experienced analysts from varied areas of
expertise.
Contact US
John Watson Head of Business Development Reports
And Data Web www.reportsanddata.com Direct
Line 1-212-710-1370 E-mail sales_at_reportsanddata
.com
www.reportsanddata.com